CR20150637A - Tratamiento de enfermedades miopaticas y neurodegenerativas por agregación de proteina mediante administración parenteral - Google Patents

Tratamiento de enfermedades miopaticas y neurodegenerativas por agregación de proteina mediante administración parenteral

Info

Publication number
CR20150637A
CR20150637A CR20150637A CR20150637A CR20150637A CR 20150637 A CR20150637 A CR 20150637A CR 20150637 A CR20150637 A CR 20150637A CR 20150637 A CR20150637 A CR 20150637A CR 20150637 A CR20150637 A CR 20150637A
Authority
CR
Costa Rica
Prior art keywords
parenteral administration
protein aggregation
miopatic
treatment
neurodegenerative diseases
Prior art date
Application number
CR20150637A
Other languages
English (en)
Inventor
Dalia Megiddo
Original Assignee
Bio Blast Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Blast Pharma Ltd filed Critical Bio Blast Pharma Ltd
Publication of CR20150637A publication Critical patent/CR20150637A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/04—Disaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se divulga un método para tratar una enfermedad asociada con agregación anormal de proteína que comprende formulaciones farmacéuticas de administración parenteral que comprende trehalosa. También se divulga una formulación farmacéutica acuosa inyectable que comprende una cantidad terapéuticamente efectiva de trehalosa.
CR20150637A 2013-05-07 2015-12-04 Tratamiento de enfermedades miopaticas y neurodegenerativas por agregación de proteina mediante administración parenteral CR20150637A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361820278P 2013-05-07 2013-05-07
PCT/IL2014/050411 WO2014181333A2 (en) 2013-05-07 2014-05-07 Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose

Publications (1)

Publication Number Publication Date
CR20150637A true CR20150637A (es) 2016-04-05

Family

ID=51022384

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150637A CR20150637A (es) 2013-05-07 2015-12-04 Tratamiento de enfermedades miopaticas y neurodegenerativas por agregación de proteina mediante administración parenteral

Country Status (15)

Country Link
US (4) US10493023B2 (es)
EP (2) EP4218769A3 (es)
JP (4) JP6837835B2 (es)
KR (1) KR20160009617A (es)
AU (4) AU2014264228A1 (es)
CA (2) CA2911399A1 (es)
CR (1) CR20150637A (es)
EA (1) EA201501054A1 (es)
HK (1) HK1217300A1 (es)
IL (1) IL241757B (es)
MD (1) MD20150120A2 (es)
MX (1) MX2015015355A (es)
PE (1) PE20160012A1 (es)
SG (1) SG11201509030TA (es)
WO (1) WO2014181333A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220288096A1 (en) * 2013-05-07 2022-09-15 Seelos Therapeutics, Inc. Compositions and methods for treating an aggregation disease or disorder
US10493023B2 (en) 2013-05-07 2019-12-03 Seelos Therapeutics, Inc. Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
US9084720B2 (en) * 2013-05-07 2015-07-21 BioBlast Pharma Ltd. Compositions and methods for treating oculopharyngeal muscular dystrophy
JP6983181B2 (ja) * 2016-02-08 2021-12-17 ジュナクソ，インコーポレーテッド 神経性疾患を治療するためのトレハロースの使用
NZ748599A (en) 2016-04-21 2022-08-26 Baylor College Medicine Compositions and methods for the treatment of lysosomal storage disorders and disorders characterized by lysosomal dysfunction
EA202090510A1 (ru) 2017-08-14 2020-06-08 Приления Ньюротерапьютикс Лтд. Способ лечения бокового амиотрофического склероза придопидином
WO2019143685A1 (en) 2018-01-16 2019-07-25 Women & Infants Hospital Of Rhode Island Methods and compositions for treating pre-eclampsia
CN115103676A (zh) * 2020-02-13 2022-09-23 普瑞尼亚神经治疗有限公司 使用普利多匹定和另一种激活剂治疗肌萎缩侧索的组合疗法
WO2022013940A1 (ja) * 2020-07-14 2022-01-20 オリンパス株式会社 嚥下検査用システム、嚥下検査方法及び嚥下検査プログラムを記録した記録媒体
WO2024118797A1 (en) * 2022-11-30 2024-06-06 Seelos Therapeutics, Inc. Trehalose for treating huntington's disease

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3782404A (en) 1972-06-14 1974-01-01 Commercial Shearing Adjustable, metered, directional flow control arrangements
JPS516109B2 (es) 1972-12-28 1976-02-25
JPS516109A (en) 1974-07-05 1976-01-19 Toshiba Tungaloy Co Ltd Aruminaatankachitan chitsukachitankeishoketsugokin
JP4033510B2 (ja) 1995-12-27 2008-01-16 ロート製薬株式会社 トレハロースを含有する眼科用医薬組成物
AU1172097A (en) 1995-12-27 1997-07-28 Rohto Pharmaceutical Co., Ltd. Pharmaceutical composition containing trehalose
JP3455633B2 (ja) 1996-06-28 2003-10-14 味の素ファルマ株式会社 潰瘍性大腸炎の予防又は治療剤
US6440446B1 (en) 1998-04-22 2002-08-27 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Agent for anti-osteoporosis
US6602865B1 (en) 1998-11-16 2003-08-05 Ivax Drug Research Institute, Ltd. Pyridazino(4,5-b)(1,5)oxazepinone, -thiazepinone and -diazepinone compounds
JP2001302517A (ja) * 2000-04-24 2001-10-31 Tokyo Univ Of Pharmacy & Life Science 脳浮腫の予防治療薬
CA2355814C (en) 2000-09-14 2010-06-29 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Pharmaceutical composition for ophthalmic use
JP4754066B2 (ja) 2000-12-22 2011-08-24 株式会社林原生物化学研究所 抗関節障害剤
JP4255101B2 (ja) 2002-03-15 2009-04-15 独立行政法人理化学研究所 神経変性疾患の治療薬
JP2006514954A (ja) * 2002-12-31 2006-05-18 ネクター セラピューティクス 抗体含有粒子及び組成物
WO2004071472A1 (ja) 2003-02-13 2004-08-26 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo α,α−トレハロースの糖質誘導体を含有することを特徴とする皮膚外用剤
US20050215562A1 (en) * 2003-06-23 2005-09-29 Patrick Tremblay Methods for treating protein aggregation disorders
US20050100637A1 (en) 2003-11-12 2005-05-12 Robert Murray Carbohydrate and electrolyte replacement composition
US20060099567A1 (en) * 2004-04-08 2006-05-11 Biomatrica, Inc. Integration of sample storage and sample management for life science
US20060257391A1 (en) * 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
AU2006247351A1 (en) 2005-05-13 2006-11-23 Whitehead Institute For Biomedical Research Modulators of alpha-synuclein toxicity
MY142987A (en) 2005-06-08 2011-02-14 Hayashibara Biochem Lab Solution for tissue adhesion prevention and method for tissue adhesion prevention
JP2006342108A (ja) * 2005-06-09 2006-12-21 Mitsubishi Chemicals Corp アミロスフェロイドにより発生する疾患の予防治療剤
JP5106109B2 (ja) 2005-08-11 2012-12-26 株式会社林原 コラーゲン産生増強剤とその用途
EP1958612B1 (en) 2005-11-30 2014-07-02 The Nisshin OilliO Group, Ltd. Trehalose fatty acid ester composition
JP4950521B2 (ja) 2006-03-08 2012-06-13 公益財団法人野口研究所 トレハロース誘導体とその製造法
KR101412082B1 (ko) 2006-03-27 2014-06-26 가부시키가이샤 도우사 고가쿠 겐큐쇼 트레할로스 화합물 및 그 화합물을 함유하는 의약
CN100571707C (zh) 2006-07-24 2009-12-23 凌沛学 含有海藻糖的关节腔内注射给药制剂
EP2123662B1 (en) 2007-01-31 2013-12-04 Glytech, Inc. Trehalose compound, process for production of the compound, and immuno-stimulative agent comprising the compound
EP2198869B1 (en) * 2007-02-23 2015-09-16 Next 21 K.K. Trehalose for the treatment or prevention of vasospasm
WO2008133884A2 (en) 2007-04-23 2008-11-06 Combinatorx, Incorporated Methods and compositions for the treatment of neurodegenerative disorders
CA2703946A1 (en) * 2007-10-31 2009-05-07 Diffusion Pharmaceuticals Llc A new class of therapeutics that enhance small molecule diffusion
JP2009249292A (ja) * 2008-04-01 2009-10-29 Toray Ind Inc ポリリン酸を安定化剤とするエリスロポエチン溶液製剤
US20110142799A1 (en) * 2008-06-23 2011-06-16 President And Fellows Of Harvard College Modulation of neurodegenerative disease by modulating xbp-1 activity
KR101021078B1 (ko) * 2008-07-22 2011-03-14 포항공과대학교 산학협력단 이노시톨 또는 트리할로스 유도체 및 이를 함유하는 퇴행성뇌신경계 질환 치료용 약학 조성물
JP5552056B2 (ja) 2008-10-31 2014-07-16 株式会社糖鎖工学研究所 トレハロース化合物、その製造方法、及び該化合物を含有する医薬
JP5933975B2 (ja) * 2008-11-12 2016-06-15 メディミューン，エルエルシー 抗体製剤
EP2248518B1 (en) 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
EP2458990B1 (en) * 2009-07-28 2016-03-30 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
JP5869882B2 (ja) 2010-03-05 2016-02-24 株式会社林原 インスリン抵抗性の予防及び／又は改善剤
CN101914118B (zh) 2010-08-06 2012-07-04 山东大学 海藻糖衍生物及其制备方法与应用
WO2012061907A2 (en) * 2010-11-10 2012-05-18 Katholieke Universiteit Leuven Osteoclast activity
US9186356B2 (en) 2011-01-08 2015-11-17 Academia Sinica Methods for treating frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U)
US8623839B2 (en) * 2011-06-30 2014-01-07 Depuy Mitek, Llc Compositions and methods for stabilized polysaccharide formulations
US20130310467A1 (en) 2012-03-06 2013-11-21 The Nisshin Oillio Group, Ltd. Trehalose fatty acid ester composition
JP5432322B2 (ja) 2012-05-08 2014-03-05 株式会社大塚製薬工場 トレハロース含有肺塞栓形成予防用哺乳動物細胞懸濁液
US20130312784A1 (en) 2012-05-24 2013-11-28 For Your Ease Only, Inc. Cosmetic organizer
US20140032304A1 (en) 2012-07-27 2014-01-30 Google Inc. Determining a correlation between presentation of a content item and a transaction by a user at a point of sale terminal
JP2014139160A (ja) 2012-12-21 2014-07-31 Masaaki Hayashibara 脳機能改善剤及び脳機能改善用食品
US9084720B2 (en) 2013-05-07 2015-07-21 BioBlast Pharma Ltd. Compositions and methods for treating oculopharyngeal muscular dystrophy
US10493023B2 (en) 2013-05-07 2019-12-03 Seelos Therapeutics, Inc. Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
JP6130224B2 (ja) 2013-05-27 2017-05-17 公益財団法人微生物化学研究会 新規化合物レンツトレハロース、その製造方法、及びその用途、並びに、新規微生物
TWI507197B (zh) 2013-07-17 2015-11-11 Univ Nat Taiwan Normal 醫藥組成物於製備不正常多麩醯胺聚集類疾病之藥物上之用途
US20160303150A1 (en) 2015-04-16 2016-10-20 BioBlast Pharma Ltd. Deuterated trehalose formulations and uses thereof

Also Published As

Publication number Publication date
HK1217300A1 (zh) 2017-01-06
US20240009113A1 (en) 2024-01-11
CA2911399A1 (en) 2014-11-13
JP2019142907A (ja) 2019-08-29
MX2015015355A (es) 2016-07-18
EP4218769A2 (en) 2023-08-02
AU2023200303A1 (en) 2023-02-23
AU2014264228A1 (en) 2015-11-12
JP2016518403A (ja) 2016-06-23
CA3239805A1 (en) 2014-11-13
WO2014181333A3 (en) 2015-01-08
JP6837835B2 (ja) 2021-03-03
AU2020277197A1 (en) 2020-12-24
EP2994145A2 (en) 2016-03-16
SG11201509030TA (en) 2015-11-27
US20190374463A1 (en) 2019-12-12
MD20150120A2 (ro) 2016-03-31
US10493023B2 (en) 2019-12-03
AU2019204513B2 (en) 2020-09-10
KR20160009617A (ko) 2016-01-26
PE20160012A1 (es) 2016-02-14
US10869831B2 (en) 2020-12-22
WO2014181333A2 (en) 2014-11-13
EP4218769A3 (en) 2023-10-18
US20220117883A1 (en) 2022-04-21
JP2021152032A (ja) 2021-09-30
EP2994145B1 (en) 2023-01-04
US20160120798A1 (en) 2016-05-05
IL241757B (en) 2020-05-31
EA201501054A1 (ru) 2016-04-29
AU2019204513A1 (en) 2019-07-18
JP2023040211A (ja) 2023-03-22

Similar Documents

Publication Publication Date Title
CR20150637A (es) Tratamiento de enfermedades miopaticas y neurodegenerativas por agregación de proteina mediante administración parenteral
DOP2016000150A (es) Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen, así como su uso para la preparación de medicamentos
PH12016500582A1 (en) Heterocyclic compounds and uses thereof
NI201600071A (es) Compuestos de inhibidor de autotaxina
CL2016000055A1 (es) Métodos para tratar o prevenir afecciones oftalmológicas
CL2015002485A1 (es) Uso de agonistas de receptor de péptido formilo 2 para tratar enfermedades inflamatorias oculares
EA201790398A1 (ru) Способы лечения заболевания печени
CR20150481A (es) Composición farmacéutica de clorhidrato de s-ketamina
CR20150480A (es) Composición farmacéutica de clorhidrato de s-cetamina
EA201991484A1 (ru) Лекарственные формы энзалутамида
EA201591751A1 (ru) Трипептидные эпоксикетонные ингибиторы протеазы
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
PE20151526A1 (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod
EA201691860A1 (ru) Пептидный медикамент в виде сухого порошка
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
BR112016028316A2 (pt) composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento
BR112015023694A2 (pt) entrega craniana de fármacos
CL2015003431A1 (es) Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales
CL2016001167A1 (es) Uso de un implante bioerosionable para tratar enfermedades oculares.
WO2014107737A3 (en) Local delivery of il-17 inhibitors for treating ocular disease
TR201310724A2 (tr) Linagliptinin farmasotik formulasyonları.
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol